Leukemia Clinical Trial
Official title:
A Feasibility Study of White Blood Cell Transfusion for the Prevention of Infection in Acute Myelogenous Leukemia Patients Undergoing Front-Line or First Salvage Induction Therapy
Patients with leukemia often have low white blood cell counts after chemotherapy, which puts
them at greater risk of infection. The standard of care for preventing infections is to give
these patients antibiotic, antifungal, and antiviral drugs during the time that white blood
cell counts are low. However, many patients still develop infections during chemotherapy.
Radiated white blood cell transfusions are a standard treatment once a patient develops a
severe infection.
The goal of this clinical research study is to learn if giving white blood cell transfusions
that are not radiated early in chemotherapy might delay or prevent infections in patients
with leukemia. Researchers also want to learn more about the type and severity of any
infections that do occur.
Study Procedures:
During each white blood cell transfusion, you will receive white blood cells from a volunteer
donor through a needle in your vein. Each transfusion will take anywhere from 1 hour to
several hours, depending on how you tolerate the treatment. You will receive a transfusion
approximately every 3-4 days (2 a week) for up to 6 weeks.
Before each white blood cell transfusion, your vital signs (temperature, heart rate,
breathing rate, and blood pressure) will be recorded according to standard evaluation of
patients with fever to look for underlying infectious causes. During and for 1 hour after the
transfusion, you will be monitored for side effects. You may be given a drug to help or
reduce any side effects. Your doctor will tell you more about any drug that may be given for
side effects.
If at any point you develop a fever while on study, blood (about 1 teaspoon) and urine will
be collected to check for infection according to standard evaluation of patients with fever
to look for underlying infectious causes. You may also have a chest x-ray. If it is abnormal
or if you have symptoms (cough, shortness of breath, nasal congestion), you may need a
computed tomography (CT) scan of the chest and/or sinuses. That will be done within 3 days of
developing a fever. If the doctor thinks it is needed, you will than have another CT scan 2
weeks later and at any other point that the doctor thinks it are needed to check for
infection.
Length of Study:
You will continue to have transfusions until the doctor thinks infection has been controlled
or until your white blood cell counts stay at a certain level for at least 2 days in a row.
If any point you are discharged from the hospital and your doctor wants you to continue
receiving white blood cell transfusions, you will be able to receive them as an outpatient.
You will be monitored for side effects and signs of infection for up to 6 weeks. You will be
taken off study if you have intolerable side effects.
This is an investigational study. Radiated white blood cell transfusions are considered to be
a standard procedure for the treatment of serious infections. It is investigational to give
unirradiated white blood cell transfusions as a way of preventing infections.
Up to 50 patients will take part in the study. All will be enrolled at MD Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |